The aim of this study is to estimate the costs of measles and measles control in 11
industrialised countries with varying levels of measles vaccine coverage. Country-specific …

Objectives To systematically review the economic evaluations of 23-valent pneumococcal
polysaccharide vaccine (PPV23) in adults aged≥ 60 years to inform the development of …

Background Polysaccharide pneumococcal vaccination for older adults is being introduced
in developed country settings. Evidence of protection by this vaccine against pneumococcal …

Vaccination of adults aged 60 years and older against Streptococcus pneumonia is not
recommended in Brazil. The 23-valent polysaccharide pneumococcal vaccine (PPV23) is …

Control of pneumococcal disease by vaccination with capsular polysaccharide has been
investigated and promoted with variable enthusiasm for the past 90 years. Despite this the …

In 2000, a multi-valent pneumococcal conjugate vaccine, known as Prevnar, was licensed
for use in infants and young children in the USA. The subsequent introduction of the vaccine …

Pneumonia is a common complication of influenza infection, and accounts for the majority of
influenza mortality. Both the WHO and the Ministry of Health in Israel prioritize seasonal …

Introduction: Smoking is the most important single risk factor for mortality in the Netherlands
and has been related to 12% of the burden of disease in Western Europe. Hence the Dutch …

Pneumococcal vaccination among the elderly is currently recommended in several western
countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of …

Introduction: Invasive pneumococcal disease is associated with substantial morbidity,
mortality and cost implications, which could be reduced by vaccination. Aim: To assess the …